BlackRock’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-6,161
| Closed | -$30.9K | – | 5531 |
|
|
2024
Q3 | $30.9K | Sell |
6,161
-344
| -5% | -$2.23K | ﹤0.01% | 4889 |
|
|
2024
Q2 | $42.9K | Hold |
6,505
| – | – | ﹤0.01% | 4894 |
|
|
2024
Q1 | $71.6K | Hold |
6,505
| – | – | ﹤0.01% | 4804 |
|
|
2023
Q4 | $87.8K | Hold |
6,505
| – | – | ﹤0.01% | 4840 |
|
|
2023
Q3 | $141K | Sell |
6,505
-2
| -0% | -$64 | ﹤0.01% | 4765 |
|
|
2023
Q2 | $251K | Hold |
6,507
| – | – | ﹤0.01% | 4674 |
|
|
2023
Q1 | $180K | Hold |
6,507
| – | – | ﹤0.01% | 4806 |
|
|
2022
Q4 | $214K | Hold |
6,507
| – | – | ﹤0.01% | 4831 |
|
|
2022
Q3 | $789K | Hold |
6,507
| – | – | ﹤0.01% | 4567 |
|
|
2022
Q2 | $1.14M | Sell |
6,507
-141
| -2% | -$29.7K | ﹤0.01% | 4485 |
|
|
2022
Q1 | $1.93M | Sell |
6,648
-10
| -0.2% | -$3.79K | ﹤0.01% | 4412 |
|
|
2021
Q4 | $3.48M | Buy |
6,658
+4,929
| +285% | +$3.54M | ﹤0.01% | 4155 |
|
|
2021
Q3 | $657K | Buy |
1,729
+4
| +0.2% | +$1.72K | ﹤0.01% | 4680 |
|
|
2021
Q2 | $1.54M | Sell |
1,725
-2,954
| -63% | -$2.26M | ﹤0.01% | 4378 |
|
|
2021
Q1 | $5.57M | Buy |
4,679
+2,150
| +85% | +$2.96M | ﹤0.01% | 3894 |
|
|
2020
Q4 | $3.36M | Buy |
2,529
+1,889
| +295% | +$2.77M | ﹤0.01% | 3860 |
|
|
2020
Q3 | $1.45M | Buy |
640
+400
| +167% | +$905K | ﹤0.01% | 3993 |
|
|
2020
Q2 | $540K | Buy |
+240
| New | +$654K | ﹤0.01% | 4193 |
|
BlackRock's BIOR Position: Q4 2024 in Review
BlackRock sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 6,161 shares — an estimated $30.9K sold.
BlackRock first reported a position in BIOR in Q2 2020 and held it in 18 quarters. The position peaked at $5.57M in Q1 2021. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- BlackRock reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 6,161 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $30.9K.
- BlackRock first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- BlackRock's Biora Therapeutics, Inc. Common Stock position peaked at $5.57M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.